Mapi Pharma to Present Series of Recent Advancements for Treating Multiple Sclerosis (MS) at ECTRIMS 2019

Mapi Pharma to Present Series of Recent Advancements for Treating Multiple Sclerosis (MS) at ECTRIMS 2019

Publication date: Sep 05, 2019

Results for Glatiramer Acetate (GA) Depot 3 year analysis in RRMS, GA Depot safety results in RRMS and PPMS, and novel anti-BMP for remyelination will be presented ECTRIMS 2019 to be held in Helsinki, Sweden on September 11-13 NESS ZIONA, Israel, Sept. 04, 2019 (GLOBE NEWSWIRE) — Mapi Pharma Ltd. , a fully integrated, late-stage clinical development biopharmaceutical company focused on introducing innovative solutions for neurological indications, announced today that the company will present recent advancements in its pipeline for treating MS at the leading MS conference, ECTRIMS 2019, which is being held in Helsinki, Sweden on September 11-13, 2019.

Ehud Marom, Chairman and Chief Executive Officer of Mapi, said, “Mapi is working to be the leading MS Company with a long acting GA Depot product for Relapsing Remitting Multiple Sclerosis (RRMS), a unique product for Primary Progressive Multiple Sclerosis (PPMS), a combination treatment of a Depot treatment and stem cells for Secondary Progressive Multiple Sclerosis (SPMS) and a novel treatment anti-BMP remyelination agent for MS. ” “We recently initiated the pivotal Phase III study of GA Depot for treating RRMS patients.

The continued strong results of GA Depot for both RRMS and PPMS demonstrate the product’s safety, tolerability, and efficacy in MS patients.

Mapi’s focus on MS encompasses several technologies ranging from oral dosage forms, for which the company has successfully launched a generic form of Fingolimod (GilenyaTM) for RRMS, to long acting Depot injections, New Chemical Entities (NCE) for remyelination, as well as combinations with stem cells.

Concepts Keywords
Acetate Manufacturing
Active Pharmaceutical Ingredients Clinical biopharmaceutical
API Chemical
APIs Injection product
Biopharmaceutical Multiple Sclerosis PPMS
BMP Organ systems
Chief Executive Officer Medical specialties
Copaxone Autoimmune diseases
Depot Injection Immunology
Fingolimod Glatiramer acetate
Frequency MAPI
Generic Drugs Injection
Helsinki Mylan
Israel BMP
LCM Stem cells
Mapi API
Multiple Sclerosis
Mylan
NASDAQ
Neurological
Patent
Pharma
Pharmaceutical
Pipeline
Stem Cells
Sweden
Tolerability

Semantics

Type Source Name
drug DRUGBANK Coenzyme M
gene UNIPROT PML
gene UNIPROT ANXA13
gene UNIPROT LARGE1
drug DRUGBANK Lincomycin
disease DOID LCM
drug DRUGBANK Fingolimod
drug DRUGBANK Alpha-1-proteinase inhibitor
drug DRUGBANK Spinosad
gene UNIPROT EHD1
disease DOID Secondary Progressive Multiple Sclerosis
disease MESH Primary Progressive Multiple Sclerosis
disease MESH Relapsing Remitting Multiple Sclerosis
drug DRUGBANK Nonoxynol-9
disease MESH development
gene UNIPROT ARID1A
disease DOID PPMS
disease DOID RRMS
drug DRUGBANK Acetate ion
drug DRUGBANK Glatiramer
disease DOID Multiple Sclerosis
disease MESH Multiple Sclerosis

Similar

Leave a Comment

Your email address will not be published. Required fields are marked *